The efficacy and tolerability of an infusion of isradipine, a calcium antagonist of the
dihydropyridine type, were tested in patients in hypertensive crisis. Ten patients with …

The renal effects of a single oral dose of placebo ν a new dihydropyridine calcium
antagonist, isradipine, were investigated in 12 patients with mild-to-moderate essential …

Isradipine is a dihydropyridine calcium-entry blocker. Previous controlled and blinded trials
have demonstrated the safety and efficacy of isradipine in lowering blood pressure in …

Isradipine, a new calcium channel blocker, was given to 32 patients with mild to moderate
essential hypertension. After a run-in period of three weeks, 32 patients were randomized …

Isradipine is a new calcium antagonist of the dihydropyridine type with marked vasodilator
activity and minimal negative inotropic effects. It is a potent antihypertensive drug when …

Isradipine is a new dihydropyridine calcium antagonist shown to be efficacious, safe, and
well tolerated in the treatment of hypertension, regardless of patient age or race. There has …

The antihypertensive, humoral, and renal effects of acute single oral administration of
placebo and isradipine, a new dihydropyridine calcium antagonist, at doses of 2.5 mg, 5.0 …

In order to investigate the efficacy of isradipine in the treatment of hypertensive crisis, we
treated three groups of patients who had diastolic blood pressure (DBP) greater than 120 …

Isradipine (Sandoz PN 200‐110), a new dihydropyridine calcium channel antagonist, was
evaluated in a randomized, double‐blind, placebo‐controlled trial for antihypertensive …

Twenty-three middle-aged men (59+/-2 years) with sustained, essential hypertension (WHO
Stage II) and with diastolic blood pressure exceeding 100mmHg during a run-in placebo …